Quantification of 4-Beta-hydroxycholesterol in Human Plasma Using Automated Sample Preparation and LC-ESI-MS/MS Analysis
Angela K. Goodenough,Joelle M. Onorato,Zheng Ouyang,Shu Chang,A. David Rodrigues,Sreeneeranj Kasichayanula,Shu-Pang Huang,Wesley Turley,Richard Burrell,Marc Bifano,Mohammed Jemal,Frank LaCreta,Adrienne Tymiak,David Wang-Iverson
DOI: https://doi.org/10.1021/tx2001898
2011-01-01
Chemical Research in Toxicology
Abstract:It has recently been proposed that plasma levels of 4 beta-hydroxycholesterol (4 beta HC) may be indicative of cytochrome P450 3A4 (P450 3A) activity and therefore could be used to probe for P450 3A-mediated drug-drug interactions. With this in mind, we describe a highly sensitive and precise liquid chromatography-electrospray ionization-tandem mass spectrometry method for the measurement of 4 beta HC in human plasma with a lower limit of quantification established at 2 ng/mL using 50 mu L of plasma. The entire sample preparation scheme including saponification and derivatization of 4 beta HC to the corresponding dipicolinyl ester (DPE) was completed in less than 8 h using an automated sample preparation scheme enabling higher-throughput capabilities. Chromatographic resolution of 4 beta HC from 4 alpha-hydroxycholesterol and other endogenous isobaric species was achieved in 11-min using an isocratic gradient on a C18 column. Because of endogenous concentrations of 4 beta HC in plasma, a stable isotope labeled (SIL) analogue, d7-4 beta HC, was used as a surrogate analyte and measured in the standard curve and quality control samples prepared in plasma. A second SIL analogue, d4-4 beta HC, was used as the internal standard. The intraday and interday accuracy for the assay was within 6% of nominal concentrations, and the precision for these measurements was less than 5% relative standard deviation. Rigorous stability assessments demonstrated adequate stability of endogenous 4 beta HC in plasma and the corresponding DPE derivative for the analysis of clinical study samples. The results from clinical samples following treatment with a potent P450 3A inducer (rifampin) or inhibitor (ketoconazole) are reported and demonstrate the potential future application for this highly precise and robust analytical assay.